A gene result informs care but does not determine one inevitable visual future.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Begin with symptoms and differential diagnosis
Many IRDs are monogenic, but variable expression, penetrance and environmental factors make the original deterministic “one defect fixes the fate” claim misleading. Bilateral similarity supports a pattern, not proof; marked asymmetry prompts assessment for trauma, syphilis or other infection and vascular disease without automatically excluding IRD. 1
Ask about reading and faces, navigation and stumbling, dark adaptation in a cinema or power outage, colour change, onset and progression. Pigmented vitreous cells can be degenerative RPE migration rather than vitritis; identify cells and the whole inflammatory picture before steroids. Genuine uveitis can coexist. RP bone-spicule pigment, attenuated vessels and waxy disc pallor may be absent early. 1
02Read the pedigree without overpromising
A negative family history does not exclude recessive disease, a new variant or an unrecognised affected relative. In a usual heterozygous AD model transmission risk is 50% per pregnancy; for AR disease 25% applies when both parents carry relevant variants in the same gene, not merely because both look healthy. RHO, ABCA4 and USH2A illustrate different models; the original claim that AR is always the most common depends on the population. 1
X-linked variants are not passed from father to son through the father’s X. A carrier mother can transmit to 50% of sons; females may also manifest disease. Mitochondrial-DNA variants follow maternal transmission, but heteroplasmy and penetrance mean not every child necessarily develops the same disease. Do not equate a mitochondrial mechanism with mitochondrial-DNA inheritance. 1
The original>100 RP genes and 60–80% molecular yield are historical, cohort-dependent figures rather than a fixed current catalogue or promised result. One gene such as ABCA4 can produce several phenotypes; a phenotype can involve many genes. Counselling precedes and follows testing; an uncertain variant or negative panel is not a definitive diagnosis or exclusion. 1
03Combine imaging with functional testing
FAF depicts fluorophore-related signal, not a direct binary map of living/dead RPE: hyperautofluorescence is not always lipofuscin stress and darkness can reflect blocking as well as loss. An RP ring and OCT ellipsoid-zone preservation help describe structure and central function, without predicting the whole field or future vision alone. 1
Full-field ERG compares dark-adapted and light-adapted retinal responses; it is a system test, not an isolated rod count. Select kinetic Goldmann or static fields for the clinical question and ability. Original V4e140° and I4e120° lack a specified meridian, eye and measurement convention; they are not universal normal widths or proof that kinetic testing always outperforms 30-2 statics. 1
04Connect phenotype and disease-specific limits
RP usually begins with rod-predominant night/peripheral difficulty; RHO(AD), USH2A(AR) and RPGR(X-linked) are examples. USH2A can occur with or without hearing impairment. LCA can present in infancy with severe dysfunction, nystagmus, oculodigital behaviour and markedly reduced ERG despite a relatively normal early fundus. Luxturna/voretigene neparvovec is not a cure for all LCA: biallelic RPE65 disease, sufficient viable retina and specialist eligibility assessment matter. 1 2
ABCA4-associated Stargardt disease can show pisciform flecks, evolving FAF and central loss; a dark choroid is neither obligatory nor a reason to require angiography in every case. High-dose vitamin A is not a treatment recommendation; the original absolute prohibition does not mean eliminating normal dietary vitamin A. Discuss supplements individually. 1 2
BEST1-related vitelliform disease can cause metamorphopsia and secondary CNV. An abnormal EOG with a relatively preserved full-field ERG is a clue, not a stand-alone gene diagnosis. “Highest CNV risk” is unverified; anti-VEGF may help neovascular complications, but 1–2 injections are not a guaranteed course. RS1 retinoschisis can show an electronegative ERG(b-wave<a-wave), not invariably. CNGA3/CNGB3 achromatopsia causes photophobia, colour and cone-response deficits with nystagmus; “stationary” does not exclude all structural progression. 1 2
| Disease | Example gene | Symptoms | Test clue | Boundary |
|---|---|---|---|---|
| RP | RHO, USH2A | Night/peripheral loss | Rod responses often reduced | Pigment/PSC; hearing phenotype varies |
| LCA | RPE65, CEP290 | Severe infant dysfunction | ERG markedly reduced | Early bland fundus; Luxturna only selected RPE65 disease |
| Stargardt | ABCA4 | Central loss | ERG depends on extent/stage | Dark choroid optional; no high-dose vitamin-A treatment |
| Best | BEST1 | Metamorphopsia | EOG abnormal/ERG may be normal | CNV possible; highest risk/1–2 injections not established |
| Retinoschisis | RS1 | Young visual loss | b-wave<a-wave may occur | Layer split, not every ERG negative |
| Achromatopsia | CNGA3/CNGB3 | Photophobia/colour deficit | Cone responses severely reduced | Nystagmus, not invariably structurally stationary |
05Treat the complication rather than a reflex diagnosis
RP-associated cystoid macular oedema is not synonymous with uveitis. Original 25% prevalence and acetazolamide 500 mg split 250/250 mg are contextual, unverified lecture examples, not a universal prescription. Oral or topical carbonic-anhydrase inhibition, including dorzolamide, requires selected assessment and monitoring; methazolamide is not an automatic safe substitute. Steroid pressure/cataract risks matter, but “never intravitreal steroids” is not a universal rule. 1
Early posterior subcapsular cataract may be treatable, with counselling about retinal visual limits, zonular weakness/phacodonesis, capsular phimosis and postoperative oedema risk. Coats-like peripheral exudation may require selected laser or cryotherapy; neither every lesion nor every patient needs the same intervention. 1
06Plan rehabilitation and honest counselling
Do not predict blindness within 1 year from the diagnosis alone or guarantee retained orientation to everyone. Low-vision care, lighting, mobility support and individually tried filters can help practical goals; filters are not essential for all. Seeing AI and Be My Eyes are original assistive-app examples, not verified current availability, privacy or benefit endorsements. Genetic counselling supports family planning and genotype-specific trial/therapy assessment without promising eligibility or cure. 1
What are the main learning points?
A gene result informs care but does not determine one inevitable visual future.
When is assessment urgent?
Sudden visual loss, new distortion, pain or inflammatory signs need prompt assessment rather than attribution to inherited degeneration.
References and access status
- 1Immutable original export; inherited retinal and choroidal dystrophy export
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2EMA Luxturna EPAR: selected indication overview
Official overview indication/viable-retina passages read 17November 2026; not full current SmPC or primary trial appraisal.
Original lecture link
For patients
Inherited disease can affect central, peripheral, night or colour vision. Testing and rehabilitation are tailored to your pattern and goals.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
Sudden visual loss, new distortion, pain or inflammatory signs need prompt assessment rather than attribution to inherited degeneration.
Sudden visual loss, new distortion, pain or inflammatory signs need prompt assessment rather than attribution to inherited degeneration.